MariTide vs Tirzepatide
How MariTide and Tirzepatide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
MariTide and Tirzepatide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
MariTide vs Tirzepatide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | MariTide | Tirzepatide |
|---|---|---|
| What it is | Long-acting GLP-1 receptor agonist and GIP receptor antagonist peptide-antibody conjugate | Synthetic dual GIP/GLP-1 receptor agonist (a 39-amino-acid once-weekly injectable peptide) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Chronic weight management; Obesity with type 2 diabetes | Type 2 diabetes (Mounjaro); Chronic weight management in obesity/overweight (Zepbound); Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound) |
| US regulatory status (2026) | investigational (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Type 2 diabetes (Mounjaro), Chronic weight management in obesity/overweight (Zepbound), Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 261 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Gastrointestinal adverse events were common in Phase 2, especially nausea, vomiting, diarrhea, and constipation. Lower starting doses and gradual dose escalation reduced these problems, but the candidate has no approved label and no post-marketing safety record. Phase 3 is testing whether a slower start can keep the weight-loss effect while making treatment easier to tolerate. | Tirzepatide's most common side effects are gastrointestinal: nausea, diarrhea, vomiting and constipation, heaviest while the dose is being raised and usually settling as the body adjusts. Less common but serious are acute pancreatitis, gallbladder disease, dehydration that can injure the kidneys, and low blood sugar when it is paired with insulin or a sulfonylurea. It carries a boxed warning for thyroid C-cell tumors seen in rats (human relevance unknown) and must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The approved pen is the product the trials measured; self-mixed "research" powder is a separate, untested risk. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Tirzepatide
Tirzepatide is FDA-approved (as of Jul 2026); MariTide is investigational in the US, so it isn't available as an approved prescription.
References
- 1.Jastreboff et al., 2025 — Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity (PMID 40549887)
- 2.Véniant et al., 2024 — GIPR antagonist conjugated to GLP-1 analogues (PMC10896721)
- 3.NCT05669599 — Phase 2 dose-ranging study of AMG 133
- 4.NCT06858839 — MARITIME-1 Phase 3 study
- 5.NCT06858878 — MARITIME-2 Phase 3 study
- 6.FDA UNII record — maridebart cafraglutide (Z24U3U73HN)